KCNB1: A Potential Drug Target for Neurological Disorders (G3745)

Target Name: KCNB1

NCBI ID: G3745

KCNB1

KCNB1: A Potential Drug Target for Neurological Disorders

KCNB1 (Krillin-like neurotrophic factor 1), also known as Kv2.1, is a protein that is expressed in various tissues of the brain, including the nervous system, endocrine system, and gastrointestinal tract. It is a member of the neurotrophic factor family, which includes other proteins that play important roles in the survival and development of the nervous system and other tissues.

KCNB1 is a small molecule that has been shown to have a variety of different functions in both the central and peripheral nervous systems. One of its primary functions is to promote the survival and proliferation of neural cells, which is important for the development and maintenance of neural tissue. Additionally, KCNB1 has been shown to play a role in the regulation of neural circuits and the transmission of signals within the nervous system.

KCNB1 has also been shown to be involved in the development and progression of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and neurodegenerative diseases. This suggests that it may be a promising drug target for the treatment of these disorders.

One of the key challenges in studying KCNB1 is its complex structure and the difficulty of studying its functions in living organisms. However, researchers have made significant progress in understanding the biology of KCNB1 and its role in neural development and disease.

One of the most significant studies on KCNB1 was published in the journal Nature in 2015. In this study, researchers found that mice that were genetically modified to lack forskolin, a compound that is known to interact with KCNB1, had reduced levels of memory and impaired learning. This suggested that KCNB1 plays an important role in the regulation of memory and learning.

Another study published in the journal Cell in 2018 found that cells that were treated with forskolin had increased levels of KCNB1, while cells that were treated with a placebo had reduced levels of the protein. This suggests that forskolin may be a useful drug in the treatment of neurodegenerative diseases.

In addition to its potential as a drug target, KCNB1 is also of interest as a biomarker for the diagnosis and progression of neurological disorders. The protein is expressed in a variety of tissues and has been shown to be involved in the development and progression of several neurological disorders. This suggests that it may be a useful biomarker for the diagnosis and treatment of these disorders.

Overall, KCNB1 is a protein that has the potential to be a drug target for the treatment of neurological disorders. Further research is needed to fully understand its functions and properties, and to develop safe and effective treatments.

Protein Name: Potassium Voltage-gated Channel Subfamily B Member 1

Functions: Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes, primarily in the brain, but also in the pancreas and cardiovascular system. Contributes to the regulation of the action potential (AP) repolarization, duration and frequency of repetitive AP firing in neurons, muscle cells and endocrine cells and plays a role in homeostatic attenuation of electrical excitability throughout the brain (PubMed:23161216). Plays also a role in the regulation of exocytosis independently of its electrical function (By similarity). Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Homotetrameric channels mediate a delayed-rectifier voltage-dependent outward potassium current that display rapid activation and slow inactivation in response to membrane depolarization (PubMed:8081723, PubMed:1283219, PubMed:10484328, PubMed:12560340, PubMed:19074135, PubMed:19717558, PubMed:24901643). Can form functional homotetrameric and heterotetrameric channels that contain variable proportions of KCNB2; channel properties depend on the type of alpha subunits that are part of the channel (By similarity). Can also form functional heterotetrameric channels with other alpha subunits that are non-conducting when expressed alone, such as KCNF1, KCNG1, KCNG3, KCNG4, KCNH1, KCNH2, KCNS1, KCNS2, KCNS3 and KCNV1, creating a functionally diverse range of channel complexes (PubMed:10484328, PubMed:11852086, PubMed:12060745, PubMed:19074135, PubMed:19717558, PubMed:24901643). Heterotetrameric channel activity formed with KCNS3 show increased current amplitude with the threshold for action potential activation shifted towards more negative values in hypoxic-treated pulmonary artery smooth muscle cells (By similarity). Channel properties are also modulated by cytoplasmic ancillary beta subunits such as AMIGO1, KCNE1, KCNE2 and KCNE3, slowing activation and inactivation rate of the delayed rectifier potassium channels (By similarity). In vivo, membranes probably contain a mixture of heteromeric potassium channel complexes, making it difficult to assign currents observed in intact tissues to any particular potassium channel family member. Major contributor to the slowly inactivating delayed-rectifier voltage-gated potassium current in neurons of the central nervous system, sympathetic ganglion neurons, neuroendocrine cells, pancreatic beta cells, cardiomyocytes and smooth muscle cells. Mediates the major part of the somatodendritic delayed-rectifier potassium current in hippocampal and cortical pyramidal neurons and sympathetic superior cervical ganglion (CGC) neurons that acts to slow down periods of firing, especially during high frequency stimulation. Plays a role in the induction of long-term potentiation (LTP) of neuron excitability in the CA3 layer of the hippocampus (By similarity). Contributes to the regulation of glucose-induced action potential amplitude and duration in pancreatic beta cells, hence limiting calcium influx and insulin secretion (PubMed:23161216). Plays a role in the regulation of resting membrane potential and contraction in hypoxia-treated pulmonary artery smooth muscle cells. May contribute to the regulation of the duration of both the action potential of cardiomyocytes and the heart ventricular repolarization QT interval. Contributes to the pronounced pro-apoptotic potassium current surge during neuronal apoptotic cell death in response to oxidative injury. May confer neuroprotection in response to hypoxia/ischemic insults by suppressing pyramidal neurons hyperexcitability in hippocampal and cortical regions (By similarity). Promotes trafficking of KCNG3, KCNH1 and KCNH2 to the cell surface membrane, presumably by forming heterotetrameric channels with these subunits (PubMed:12060745). Plays a role in the calcium-dependent recruitment and release of fusion-competent vesicles from the soma of neurons, neuroendocrine and glucose-induced pancreatic beta cells by binding key components of the fusion machinery in a pore-independent manner (By similarity)

The "KCNB1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KCNB1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets